(vianews) - equasens (eqs.pa) is among this list of stock assets with the highest dividend rate and return on equity on the healthcare sector.
| financial asset | price | forward dividend yield | return on equity |
|---|---|---|---|
| equasens (eqs.pa) | €51.30 | 2.33% | 23.04% |
| vetoquinol (veto.pa) | €99.50 | 0.9% | 10.98% |
several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. equasens (eqs.pa)
2.33% forward dividend yield and 23.04% return on equity
equasens société anonyme provides healthcare it solutions in europe. it offers id. patient, a business software; id. mobility, a back-office management software; pandalab pro, an instant messaging solution; id. vente, an has-certified drug database; id. commande, an order management module; dispensing robots; services ségur id; id. dosage, a dosage management and printing module; multimeds reconditioning robot; compliance monitoring module; home delivery module; home equipment rental management module; visiodroits module; and website connector. the company also provides id. desk, an informative and interactive dashboard; id. up!, a real-time monitoring and control application of id management software; id. easyq, a queue management solution; miaterapia; id. show, an application for managing real-time communications on pharmacy screens; pharmaweb; tsgatepro; lmo, a dispensary business software; and lgo, a dispensary management software. in addition, it offers domilink had software; mobisoins mobility tool; memorialis, support software for alzheimer's monitoring teams; hospilink, an hospital information system applications; hospilink dpi, a computerized patient file; hospilink lookup big data; enephro solutions; noviacare solutions; kap&link2, a contact chip card reader terminal and nfc reader; es-kap-ad, a connected nomadic tool incorporating software; kap-inside, a mobile terminal; and ti-kap allowing access to contact and contactless cards. further, the company provides authenticator, a patented authentication system; kap'teur by kapelse, a patented universal sensor; expressvitale; médistory, that automates the transfer of invoicing to the healthcare professional's accounting. additionally, it offers medical telesecretarial services for healthcare professionals, as well as equipment lease financing solutions. the company was incorporated in 1996 and is headquartered in villers-les-nancy, france. equasens société anonyme is a subsidiary of marque verte sante.
earnings per share
as for profitability, equasens has a trailing twelve months eps of €3.2.
pe ratio
equasens has a trailing twelve months price to earnings ratio of 16.03. meaning, the purchaser of the share is investing €16.03 for every euro of annual earnings.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 23.04%.
more news about equasens.
2. vetoquinol (veto.pa)
0.9% forward dividend yield and 10.98% return on equity
vetoquinol sa, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in europe, the americas, and the asia pacific region. it provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. the company was founded in 1933 and is headquartered in lure, france. vetoquinol sa is a subsidiary of soparfin sca.
earnings per share
as for profitability, vetoquinol has a trailing twelve months eps of €4.97.
pe ratio
vetoquinol has a trailing twelve months price to earnings ratio of 20.02. meaning, the purchaser of the share is investing €20.02 for every euro of annual earnings.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.98%.
moving average
vetoquinol's value is above its 50-day moving average of €98.68 and above its 200-day moving average of €96.10.yearly top and bottom value
vetoquinol's stock is valued at €99.50 at 12:30 est, under its 52-week high of €110.00 and way higher than its 52-week low of €76.30.
more news about vetoquinol.